A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Cogent Biosciences, Inc.
Cogent Biosciences, Inc.
Novartis
Eli Lilly and Company
Hoffmann-La Roche
AstraZeneca
Seagen Inc.
Merck Sharp & Dohme LLC
TCR2 Therapeutics
TCR2 Therapeutics
Toray Industries, Inc
Eli Lilly and Company
Lisata Therapeutics, Inc.
Compass Therapeutics
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc